PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19714314-4 2009 Mouse or human CD4(+) T cells were cultured with immobilized anti-CD3/CD28 antibodies in the presence of tacrolimus. Tacrolimus 105-115 CD28 molecule Homo sapiens 70-74 19420299-8 2009 Calcineurin activity increased significantly from 1214 +/- 111 to 1652 +/- 138 fmol/microg/min; addition of either tacrolimus or CsA (500 ng/ml) blocked CD3/CD28 stimulation. Tacrolimus 115-125 CD28 molecule Homo sapiens 157-161 11093160-9 2000 In untransformed human peripheral blood T lymphocytes, these phosphatases function through a cyclosporin A/FK506-resistant co-stimulatory signaling pathway which is common for the accessory receptors CD2 and CD28. Tacrolimus 107-112 CD28 molecule Homo sapiens 208-212 18845086-9 2008 FK506 can not only inhibit the expression of positive co-stimulatory molecules CD28 and ICOS but also promote the expression of negative co-stimulatory molecule CD152, while CsA can exert its immunosuppressive effect mainly through promoting the expression of CD152. Tacrolimus 0-5 CD28 molecule Homo sapiens 79-83 12914753-9 2003 Most interestingly, the calcineurin inhibitor, FK506, consistently inhibited CD3/CD28-induced CXCR6 down-regulation. Tacrolimus 47-52 CD28 molecule Homo sapiens 81-85 11357886-3 2001 FK506 potently inhibited IL-6 production from PBMC stimulated with anti-CD3 and anti-CD28 monoclonal antibody (anti-CD3/CD28). Tacrolimus 0-5 CD28 molecule Homo sapiens 85-89 11357886-3 2001 FK506 potently inhibited IL-6 production from PBMC stimulated with anti-CD3 and anti-CD28 monoclonal antibody (anti-CD3/CD28). Tacrolimus 0-5 CD28 molecule Homo sapiens 120-124 14709642-4 2004 METHODS: We investigated the immunosuppressive effects of tacrolimus on anti-CD3/anti-CD28 T-cell costimulation in a human whole-blood assay, analyzing T-cell proliferation, activation marker expression (CD25, CD69), IL-2 protein expression, and cytokine mRNA expression in vitro (n = 11 healthy individuals). Tacrolimus 58-68 CD28 molecule Homo sapiens 86-90 14709642-10 2004 Two individuals responded conversely, indicating that differences in the in vitro response to tacrolimus and CsA among individuals may be attributable to potential heterogeneity in the involvement of the CD28 pathway. Tacrolimus 94-104 CD28 molecule Homo sapiens 204-208 10928971-4 2000 FK506 inhibited anti-CD3/CD28 induced TNF-alpha and IL-1beta production at concentrations less than 1 ng ml(-1). Tacrolimus 0-5 CD28 molecule Homo sapiens 25-29 11053632-6 2000 Treatment with Tacr resulted in a decreased expression of costimulatory ligands and adhesion molecules (T cells: CD40L, p < 0.05; CD28 and CD54, p < or = 0.01; B cells: CD25, p = 0.05; CD40, p < 0.001; monocytes: CD40, p < 0.05), which coincided with decreased PHA-stimulated T cell IL-2 responses (398 +/- 153 versus 43 +/- 15 pg/ml, p < 0.05), impaired CD4 helper activity (117% +/- 22% versus 73% +/- 19%, p < 0.05) and increased CD4 suppressor activity (-120% +/- 28% versus -18% +/- 27%, p = 0.02). Tacrolimus 15-19 CD28 molecule Homo sapiens 133-137 10928971-7 2000 FK506 and CsA, but not DEX, specifically inhibited anti-CD3/CD28 induced inflammatory cytokine production without affecting the lipopolysaccaride (LPS) induced effect. Tacrolimus 0-5 CD28 molecule Homo sapiens 60-64 10589954-2 1999 Previous studies have shown that stimulation of T cells via CD28 or phorbol myristate acetate (PMA) activation is highly resistant to inhibition by cyclosporine A (CsA) and tacrolimus (FK506), as is the response of T cells to phytohemmaglutinin in the presence of endothelial cells. Tacrolimus 173-183 CD28 molecule Homo sapiens 60-64 10589954-2 1999 Previous studies have shown that stimulation of T cells via CD28 or phorbol myristate acetate (PMA) activation is highly resistant to inhibition by cyclosporine A (CsA) and tacrolimus (FK506), as is the response of T cells to phytohemmaglutinin in the presence of endothelial cells. Tacrolimus 185-190 CD28 molecule Homo sapiens 60-64 9878113-5 1998 However, FK506 inhibition was more pronounced on MIP-1beta than MIP-1alpha, especially in CD3/CD28-activated T cells. Tacrolimus 9-14 CD28 molecule Homo sapiens 94-98 9199340-7 1997 Similar to the upregulation of IL-2 secretion, the transcriptional upregulation of the RE/AP composite element by CD28 is FK506 insensitive. Tacrolimus 122-127 CD28 molecule Homo sapiens 114-118 9510155-8 1998 FK506 also reduced CD3/CD28-induced production of IL-3, IL-4, IL-10, TNF-alpha, and IL-6 but augmented that of GM-CSF, IL-5, IFN-gamma, and IL-13. Tacrolimus 0-5 CD28 molecule Homo sapiens 23-27 9363914-0 1997 FK506 enhances IL-13 production by T cells activated through CD3/CD28. Tacrolimus 0-5 CD28 molecule Homo sapiens 65-69 8302298-11 1994 The immunosuppressive drugs Cyclosporin A and FK506 completely blocked CD28 and CD3 mediated IL-2 production in these transfectants whereas rapamycin had only a partial inhibitory effect. Tacrolimus 46-51 CD28 molecule Homo sapiens 71-75 30036394-5 2018 RESULTS: At day 30 after transplantation, in tacrolimus-treated patients, NFATc1 amplification was inhibited in CD4+ T cells expressing the co-stimulation receptor CD28 (mean inhibition 37%; p = 0.01) and in CD8+CD28+ T cells (29% inhibition; p = 0.02), while this was not observed in CD8+CD28- T cells or belatacept-treated patients. Tacrolimus 45-55 CD28 molecule Homo sapiens 164-168 30036394-5 2018 RESULTS: At day 30 after transplantation, in tacrolimus-treated patients, NFATc1 amplification was inhibited in CD4+ T cells expressing the co-stimulation receptor CD28 (mean inhibition 37%; p = 0.01) and in CD8+CD28+ T cells (29% inhibition; p = 0.02), while this was not observed in CD8+CD28- T cells or belatacept-treated patients. Tacrolimus 45-55 CD28 molecule Homo sapiens 212-216 30036394-5 2018 RESULTS: At day 30 after transplantation, in tacrolimus-treated patients, NFATc1 amplification was inhibited in CD4+ T cells expressing the co-stimulation receptor CD28 (mean inhibition 37%; p = 0.01) and in CD8+CD28+ T cells (29% inhibition; p = 0.02), while this was not observed in CD8+CD28- T cells or belatacept-treated patients. Tacrolimus 45-55 CD28 molecule Homo sapiens 212-216 30036394-6 2018 Tacrolimus pre-dose concentrations of these patients correlated inversely with NFATc1 amplification in CD28+ T cells (rs = -0.46; p < 0.01). Tacrolimus 0-10 CD28 molecule Homo sapiens 103-107